Wedbush Downgrades Fate Therapeutics (FATE) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall St treads water as chips rise, megacaps fall ahead of Fed, Big Tech earnings
- SK Hynix shares surge after Q3 profit beats expectations
- Oil prices rise about 2% as Yemen fighting stokes supply fears
- Alphabet stock rises as OpenAI plans to buy Google's TPUs
- Wendy's shares surge 16% on $1.4 billion takeover bid by Nelson Peltz’s Trian Fund
Tweet
Share
E-mailGet Alerts FATE Hot Sheet
Price: $2.10 +1.45%
Rating Summary:
11 Buy, 13 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 5 | Down: 16 | New: 17
Rating Summary:
11 Buy, 13 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 5 | Down: 16 | New: 17
Join SI Premium – FREE
Wedbush analyst David Nierengarten downgraded Fate Therapeutics (NASDAQ: FATE) from Outperform to Neutral with a price target of $88.00.
For an analyst ratings summary and ratings history on Fate Therapeutics click here. For more ratings news on Fate Therapeutics click here.
Shares of Fate Therapeutics closed at $86.27 yesterday.
You May Also Be Interested In
- Oppenheimer Downgrades Enphase Energy (ENPH) to Perform, 'Core Business Recovery Not Materializing'
- DAM Capital Downgrades Hexaware Technologies (HEXW:IN) to Neutral
- JPMorgan Starts FANUC Corp (6954:JP) (FANUY) at Neutral
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
